Ivermectin Disrupts Stress Recovery in Neuroblastoma Cells

Researchers at McGill University have uncovered a novel mechanism by which the antiparasitic drug ivermectin may exert anticancer effects. Published in Cells on September 7, 2026, the study focuses on neuroblastoma — a rare but aggressive pediatric cancer of the nervous system — and reveals how ivermectin derails the cellular stress response by interfering with stress granule dynamics.

Stress granules are temporary assemblies of proteins and RNA that form when cells encounter environmental stress, such as heat shock or oxidative damage. Under normal conditions, these structures are dismantled once the stress subsides, a process that relies heavily on molecular chaperones like Hsp70. The McGill team found that ivermectin prolongs stress granule persistence by specifically reducing the de novo synthesis of Hsp70 in neuroblastoma cells — but not in cervical carcinoma cells — pointing to a cell-type-dependent mechanism. Patients exploring repurposed drug strategies can use the dosing calculator to contextualize preclinical findings against established protocols.

This finding adds to the growing body of evidence that ivermectin, best known as an antiparasitic agent, may have broader pharmacological applications in oncology. For a broader overview of ivermectin's potential role in cancer immunotherapy, see our detailed research review.

Table of Contents

• Study Design and Methods
• Key Findings
• Cellular Context Matters
• Clinical Implications
• Frequently Asked Questions

Study Design and Methods

The study used human neuroblastoma and cervical carcinoma (HeLa) cell lines to investigate how ivermectin affects stress granule dynamics during and after acute stress. Researchers employed multiple complementary techniques:

• Immunofluorescence microscopy to visualize stress granule formation and dissolution
• Western blotting to quantify Hsp70 and heat shock factor 1 (Hsf1) protein levels
• Quantitative PCR to measure Hsp70 transcript abundance
• Bioorthogonal Non-Canonical Amino Acid Tagging (BONCAT) to track de novo protein synthesis

Stress granules were induced using sodium arsenite, a well-established chemical stressor, followed by a recovery period. Ivermectin was applied during the recovery phase to observe its impact on stress granule clearance.

Key Findings

The research team reported three critical observations:

Crucially, ivermectin reduced Hsp70 protein synthesis without affecting the corresponding mRNA levels or the upstream transcription factor Hsf1. This suggests the drug acts at the translational level — interfering with the ribosome-mediated production of Hsp70 protein rather than its gene expression.

Cellular Context Matters

Perhaps the most important takeaway is that ivermectin's effect on stress granule clearance is cell-type dependent. In neuroblastoma cells, the drug delayed stress granule dissolution and reduced Hsp70 synthesis. In cervical carcinoma (HeLa) cells, neither effect was observed.

This context-dependency has two practical implications:

1. Tumor specificity: Ivermectin may be more effective against cancers with high dependence on Hsp70-mediated stress recovery, such as certain neuroblastoma subtypes.
2. Combination potential: Drugs that induce cellular stress (e.g., chemotherapy, radiotherapy) could be paired with ivermectin to prevent cancer cells from recovering, potentially enhancing treatment efficacy.

For patients interested in understanding how ivermectin dosing intersects with broader cancer protocols, our ivermectin dosage and safety guide provides practical context.

Clinical Implications

Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 15% of all pediatric cancer deaths. High-risk neuroblastoma remains difficult to treat, with 5-year survival rates below 50% despite intensive multimodal therapy. New therapeutic targets are urgently needed.

The McGill findings suggest that ivermectin may offer a novel angle: by blocking the cancer cell's ability to recover from stress, it could potentially amplify the damage caused by conventional treatments. However, several caveats apply:

• This is in-vitro research — cell culture experiments do not always translate to living organisms.
• No animal model data or human clinical trials are reported in this paper.
• The optimal dose and timing for achieving this effect in patients remain unknown.
• Drug interactions with standard neuroblastoma chemotherapy regimens have not been studied.

As always, preclinical findings should inform future research directions rather than guide immediate patient decisions. The study contributes mechanistic understanding but does not establish clinical efficacy.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Chu S, Anim EP, Salehi-Tabar R, White JH, Stochaj U. Ivermectin Inhibits Stress Granule Clearance by Blocking the De Novo Synthesis of Hsp70 in Neuroblastoma Cells. Cells. 2026 Sep 7;15(17):1623. doi: 10.3390/cells15171623. PMID: 42738916.

Medical Disclaimer

The content on this website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research summaries presented here are derived from peer-reviewed scientific literature and are intended to help readers understand emerging findings. They do not replace consultation with a qualified healthcare provider. Always consult a licensed physician before making any changes to your health regimen. Sanare Lab does not provide medical advice.